Trials / Completed
CompletedNCT02426333
Optimizing Abiraterone Therapy
Optimizing Abiraterone (Zytiga®) Therapy by Exploring the Relation Between an Early Biomarker - Drug Exposure - as a Predictor for Drug Response in Patients With mCRPC
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 56 (actual)
- Sponsor
- Radboud University Medical Center · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to explore whether early abiraterone exposure is related to treatment response in patients with metastatic castration resistant prostate cancer. Furthermore to explore the relation between biomarkers and treatment response and drug exposure.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Abiraterone Acetate | Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC) |
Timeline
- Start date
- 2016-01-01
- Primary completion
- 2019-04-24
- Completion
- 2019-08-01
- First posted
- 2015-04-24
- Last updated
- 2019-09-13
Locations
3 sites across 1 country: Netherlands
Source: ClinicalTrials.gov record NCT02426333. Inclusion in this directory is not an endorsement.